Cargando…

Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study

OBJECTIVE: We aimed to explore the value of Huobahuagen tablet (HBT) in improving decreased renal function for patients with diabetic kidney disease (DKD) over time. METHODS: This was a single-center, retrospective, real-world study on eligible 122 DKD patients who continued to use HBT + Huangkui ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Ying, Li, Ruihan, Zhou, Peipei, Li, Nan, Xu, Weilong, Zhou, Xiqiao, Yan, Qianhua, Yu, Jiangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315672/
https://www.ncbi.nlm.nih.gov/pubmed/37404303
http://dx.doi.org/10.3389/fendo.2023.1166880
_version_ 1785067547149729792
author Tan, Ying
Li, Ruihan
Zhou, Peipei
Li, Nan
Xu, Weilong
Zhou, Xiqiao
Yan, Qianhua
Yu, Jiangyi
author_facet Tan, Ying
Li, Ruihan
Zhou, Peipei
Li, Nan
Xu, Weilong
Zhou, Xiqiao
Yan, Qianhua
Yu, Jiangyi
author_sort Tan, Ying
collection PubMed
description OBJECTIVE: We aimed to explore the value of Huobahuagen tablet (HBT) in improving decreased renal function for patients with diabetic kidney disease (DKD) over time. METHODS: This was a single-center, retrospective, real-world study on eligible 122 DKD patients who continued to use HBT + Huangkui capsule (HKC) therapy or HKC therapy without interruption or alteration in Jiangsu Province Hospital of Chinese Medicine from July 2016 to March 2022. The primary observation outcomes included estimated glomerular filtration rate (eGFR) at baseline and 1-, 3-, 6-, 9-, and 12-month follow-up visits and changes in eGFR from baseline (ΔeGFR). Propensity score (PS) and inverse probability treatment weighting (IPTW) were used to control for confounders. RESULTS: eGFR was significantly higher in the HBT + HKC group than in the HKC alone group at the 6-, 9-, and 12-month follow-up visits (p = 0.0448, 0.0002, and 0.0037, respectively), indicating the superiority of HBT + HKC over HBT alone. Furthermore, the ΔeGFR of the HBT + HKC group was significantly higher than that of the HKC alone group at the 6- and 12-month follow-up visits (p = 0.0369 and 0.0267, respectively). In the DKD G4 patients, eGFR was higher in the HBT + HKC group at the 1-, 3-, 6-, 9-, and 12-month follow-up visits compared with baseline, with statistically significant differences at the 1-, 3-, and 6- month follow-up visits (p = 0.0256, 0.0069, and 0.0252, respectively). The fluctuations in ΔeGFR ranged from 2.54 ± 4.34 to 5.01 ± 5.55 ml/min/1.73 m(2). Change in the urinary albumin/creatinine ratio from baseline did not exhibit a significant difference between the two groups at any of the follow-up visits (p > 0.05 for all). Adverse event incidence was low in both groups. CONCLUSION: The findings of this study based on real-world clinical practice indicate that HBT + HKC therapy exhibited better efficacy in improving and protecting renal function with a favorable safety profile than HKC therapy alone. However, further large-scale prospective randomized controlled trials are warranted to confirm these results.
format Online
Article
Text
id pubmed-10315672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103156722023-07-04 Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study Tan, Ying Li, Ruihan Zhou, Peipei Li, Nan Xu, Weilong Zhou, Xiqiao Yan, Qianhua Yu, Jiangyi Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: We aimed to explore the value of Huobahuagen tablet (HBT) in improving decreased renal function for patients with diabetic kidney disease (DKD) over time. METHODS: This was a single-center, retrospective, real-world study on eligible 122 DKD patients who continued to use HBT + Huangkui capsule (HKC) therapy or HKC therapy without interruption or alteration in Jiangsu Province Hospital of Chinese Medicine from July 2016 to March 2022. The primary observation outcomes included estimated glomerular filtration rate (eGFR) at baseline and 1-, 3-, 6-, 9-, and 12-month follow-up visits and changes in eGFR from baseline (ΔeGFR). Propensity score (PS) and inverse probability treatment weighting (IPTW) were used to control for confounders. RESULTS: eGFR was significantly higher in the HBT + HKC group than in the HKC alone group at the 6-, 9-, and 12-month follow-up visits (p = 0.0448, 0.0002, and 0.0037, respectively), indicating the superiority of HBT + HKC over HBT alone. Furthermore, the ΔeGFR of the HBT + HKC group was significantly higher than that of the HKC alone group at the 6- and 12-month follow-up visits (p = 0.0369 and 0.0267, respectively). In the DKD G4 patients, eGFR was higher in the HBT + HKC group at the 1-, 3-, 6-, 9-, and 12-month follow-up visits compared with baseline, with statistically significant differences at the 1-, 3-, and 6- month follow-up visits (p = 0.0256, 0.0069, and 0.0252, respectively). The fluctuations in ΔeGFR ranged from 2.54 ± 4.34 to 5.01 ± 5.55 ml/min/1.73 m(2). Change in the urinary albumin/creatinine ratio from baseline did not exhibit a significant difference between the two groups at any of the follow-up visits (p > 0.05 for all). Adverse event incidence was low in both groups. CONCLUSION: The findings of this study based on real-world clinical practice indicate that HBT + HKC therapy exhibited better efficacy in improving and protecting renal function with a favorable safety profile than HKC therapy alone. However, further large-scale prospective randomized controlled trials are warranted to confirm these results. Frontiers Media S.A. 2023-06-19 /pmc/articles/PMC10315672/ /pubmed/37404303 http://dx.doi.org/10.3389/fendo.2023.1166880 Text en Copyright © 2023 Tan, Li, Zhou, Li, Xu, Zhou, Yan and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Tan, Ying
Li, Ruihan
Zhou, Peipei
Li, Nan
Xu, Weilong
Zhou, Xiqiao
Yan, Qianhua
Yu, Jiangyi
Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title_full Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title_fullStr Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title_full_unstemmed Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title_short Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
title_sort huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315672/
https://www.ncbi.nlm.nih.gov/pubmed/37404303
http://dx.doi.org/10.3389/fendo.2023.1166880
work_keys_str_mv AT tanying huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT liruihan huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT zhoupeipei huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT linan huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT xuweilong huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT zhouxiqiao huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT yanqianhua huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy
AT yujiangyi huobahuagentabletimprovesrenalfunctionindiabetickidneydiseasearealworldretrospectivecohortstudy